Introduction {#Sec1}
============

Acne develops via a multifactorial process involving factors such as follicular hyperkeratinization, *Propionibacterium acnes* colonization, sebum production and inflammation \[[@CR1]\]. For moderate to severe and inflammatory acne vulgaris, oral antibacterials are standard care components \[[@CR1], [@CR2]\], with tetracyclines and macrolides usually preferred \[[@CR1]--[@CR3]\]. However, these agents have certain limitations, among which are photosensitivity (tetracyclines), adverse vestibular effects (minocycline), gastrointestinal disturbances (particularly with macrolides and doxycycline) \[[@CR1]\], dysbiosis \[[@CR4]\] and microbial resistance concerns \[[@CR5]\]. Additional oral antibacterials have therefore been investigated.Key milestones in the development of sarecycline for the treatment of acne vulgaris, focussing on phase 3 trials. *NDA* new drug application

Sarecycline (Seysara™) is a new oral tetracycline-class antibiotic developed by Paratek and Allergan, and acquired by Almirall S.A., for the treatment of acne vulgaris. In October 2018 \[[@CR6]\], the US FDA approved sarecycline tablets for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years \[[@CR7]\]. Sarecycline tablets should be taken once daily (with or without food), with the recommended daily dose being based on the patient's bodyweight (60 mg if 33--54 kg, 100 mg if 55--84 kg and 150 mg if 85--136 kg) \[[@CR7]\]. Sarecycline capsules have also been studied in the USA, but no recent reports of development have been identified. There are currently no clinical trials underway assessing sarecycline in rosacea.

Company Agreements {#Sec2}
------------------

In July 2007, Warner Chilcott (now Allergan, previously Actavis) entered an agreement to develop and commercialize certain narrow-spectrum tetracyclines originated by Paratek for the treatment of acne and rosacea \[[@CR8]\]. Allergan (now Almirall) was responsible for their development and have exclusive rights to market them in the USA, while Paratek retains non-USA rights. Paratek received an up-front payment and will receive further payments at key milestones of development/regulatory approval as well as royalties on the product sales \[[@CR8]\]. Almirall acquired most of the US dermatology portfolio of Allergan (which includes sarecycline) in August 2018; the deal was worth up to \$US650 million, with \$US550 million paid upfront and a potential earn-out in 2022 of up to \$US100 million (depending on performance) \[[@CR9]\]. The acquisition was finalized in September 2018 \[[@CR10]\]. As of December 2016, the patent portfolio for Paratek\'s acne and rosacea programme (which encompasses compositions of matter, methods of use and sarecycline salts and polymorphs) included two issued US patents (8,318,706 and 8,513,223, which are expected to expire in 2031 and 2029) and corresponding foreign national or regional counterpart applications \[[@CR11]\].

Scientific Summary {#Sec3}
==================

Pharmacodynamics {#Sec4}
----------------

Sarecycline is a ribosomal protein inhibitor of the tetracycline class that displays potent activity against *P. acnes* and other Gram-positive bacteria in vitro \[[@CR12]\]. The drug has also demonstrated anti-inflammatory effects in vitro \[[@CR12]\]. These properties appear to be consistent with those of other tetracyclines, although the exact mechanism by which sarecycline acts to treat acne vulgaris is currently unknown \[[@CR7]\]. The drug was not associated with clinically relevant QT interval prolongation when used at a dose approximately threefold greater than the recommended maximum \[[@CR7]\].

Sarecycline (like other tetracyclines) may impact the bactericidal effects of penicillin; coadministration should therefore be avoided \[[@CR7]\]. Coadministering sarecycline with oral retinoids should also be avoided, as both tetracyclines and oral retinoids can increase intracranial pressure. Plasma prothrombin activity may be reduced by sarecycline (as with other tetracyclines) which could elevate the bleeding risk of patients taking anticoagulants; the dosage of the anticoagulant may therefore need to be reduced \[[@CR7]\].

Some recipients of teracyclines can experience photosensitivity \[[@CR7]\] and sarecycline has displayed photoxic potential in mice \[[@CR13]\]; patients should be advised to avoid/minimize exposure to sunlight (natural and artificial) while taking sarecycline \[[@CR7]\]. In animal toxicity studies of oral sarecycline, pigment deposition in the thyroid gland or tooth/bone discolouration were not considered to be toxicologically adverse \[[@CR13]\]; sarecycline should not be used during tooth development \[[@CR7]\].

Pharmacokinetics {#Sec5}
----------------

Sarecycline reaches maximum plasma concentrations (C~max~) in a median time of 1.5--2.0 h; the drug reaches steady state by day 7 and has a mean accumulation ratio of 1.5- to 1.6-fold with repeat dosing \[[@CR7]\]. Steady-state exposure to the drug in healthy subjects increased slightly less than proportionally when the once-daily dose was increased from 60 to 150 mg. Sarecycline can be taken with or without food, although administration of the drug with a milk-containing meal high in fat and calories reduced exposure to the drug by ≈ 30% and delayed the time to C~max~ by ≈ 0.53 h \[[@CR7]\], consistent with some other tetracycline-class drugs. Sarecycline is 62.5--74.7% protein bound in vitro and has a mean apparent volume of distribution of 91.4--97.0 L at steady state. Sarecycline is minimally metabolized by liver microsome enzymes in vitro (\< 15%); non-enzymatic epimerization, demethylation, hydroxylation and desaturation produce minor metabolites. The drug is excreted via both the faeces and the urine, with 42.6 and 44.1% of a single 100 mg oral dose being recovered via these routes (14.9 and 24.7% as unchanged sarecycline). Sarecycline has a mean elimination half-life of 21--22 h and its mean apparent oral clearance is ≈ 3 L/h at steady state \[[@CR7]\].Chemical structure of sarecycline

###### 

Features and properties of sarecycline

  ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alternative names             P0005672; P005672; Seysara; WC-3035
  Class                         Amides, antiacnes, antibacterials, naphthacenes, skin disorder therapies, small molecules, tetracyclines
  Mechanism of action           Unknown
  Route of administration       Oral
  Pharmacodynamics              Ribosomal protein inhibitor; potent activity against *Propionibacterium acnes* and other Gram-positive bacteria
  Pharmacokinetics              Reaches maximum plasma concentrations in 1.5--2.0 h and has an elimination half-life of 21--22 h
  Most frequent adverse event   Nausea
  ATC codes                     
   WHO ATC code                 J01A (tetracyclines)
   EphMRA ATC code              J1A (tetracyclines and combinations)
  Chemical name                 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-\[(methoxymethylamino)methyl\]-1,11-dioxo-, (4S,4aS,5aR,12aS)-
  ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

The pharmacokinetics of sarecycline are not impacted to any clinically relevant extent by age, sex, body weight, renal impairment or mild to moderate hepatic impairment (Child Pugh class A or B) \[[@CR7]\]. The pharmacokinetics of sarecycline have not been assessed in the setting of severe hepatic impairment (Child Pugh class C) or end-stage renal disease \[[@CR7]\].

As with other tetracyclines, sarecycline absorption may be impaired by iron-containing preparations, aluminium-, calcium- or magnesium-containing antacids or bismuth subsalicylate, necessitating separate administration \[[@CR7]\]. Sarecycline inhibits p-glycoprotein in vitro and may therefore increase concentrations of drugs that are p-glycoprotein substrates; dosage reduction and toxicity monitoring may be required if these agents are used in combination. Sarecycline does not inhibit other key transporter proteins (BCRP, OATP1B1, OATP1B3, OAT1, OAT3 or OCT2) or key CYP isoenzymes (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4/5) and is not an inducer of CYP1A2, CYP2B6 or CYP3A4/5 in vitro \[[@CR7]\].

Therapeutic Trials {#Sec6}
------------------

Sarecycline has been studied in numerous phase 1 trials, one dose-ranging phase 2 trial, two 12-week phase 3 trials (in ≈ 2000 patients) and one 40-week phase 3 safety extension study, with the phase 2 and 3 studies being the focus here. No active comparator-controlled trials have been conducted with sarecycline.

### Phase 3 {#Sec7}

After 12 weeks of treatment in a phase 3 trial in patients aged 9--45 years with moderate to severe facial acne vulgaris (study SC1401; NCT02320149), significantly more recipients of once-daily sarecycline 1.5 mg/kg (as tablets) \[*n* = 483\] than of placebo (*n* = 485) achieved treatment success on the face (21.9 vs. 10.5%; *p* \< 0.0001), defined as a ≥ 2-point decrease (improvement) from baseline in Investigator's Global Assessment (IGA) score plus an IGA score of 0 or 1 (i.e. clear or almost clear) \[[@CR14]\] \[primary endpoint \[[@CR7]\]\]. The facial success rate in this randomized, double-blind trial began to significantly favour sarecycline over placebo after 9 weeks of treatment \[[@CR14]\]. These findings were supported by changes from baseline in lesion counts at week 12, including the mean absolute change in inflammatory lesions (− 15.3 with sarecycline vs. − 10.2 with placebo; between-group statistical analyses not reported) \[primary endpoint\] \[[@CR7]\], the least-squares mean (LSM) percentage change in inflammatory lesions (− 51.8 vs. − 35.1%; *p* \< 0.0001) \[[@CR14]\] and the LSM absolute change in non-inflammatory lesions (− 15.1 vs. − 11.2%; *p* \< 0.01) \[[@CR14]\]. The benefit of sarecycline over placebo was evident as early as week 3 of treatment for the inflammatory lesion count \[[@CR7], [@CR14]\] and week 6 of treatment for the non-inflammatory lesion count \[[@CR14]\].

For those affected, acne on the chest and back also improved with sarecycline, with the rates of success (i.e. ≥ 2-point decrease in IGA score) at 12 weeks being greater (*p* \< 0.05) with the drug than with placebo (29.6 vs. 19.6% and 32.9 vs. 17.1%) \[post hoc\] \[[@CR14]\]. Sarecycline was also associated with health-related quality of life benefits, being significantly more favourable than placebo for the symptoms, emotion and total (but not functioning) score of the Skindex-16 questionnaire. At baseline, the sarecycline and placebo groups had a mean of 29.7 and 30.2 inflammatory facial lesions and a mean of 42.4 and 43.7 non-inflammatory facial lesions; overall, across groups, 39 and 55% of patients had chest or back acne (IGA score ≥ 2 at these locations) \[[@CR14]\].

These findings were supported by an identically-designed phase 3 study (SC1402; NCT02322866) \[[@CR14]\]. The rate of facial treatment success was significantly (*p* = 0.0038) greater with sarecycline (*n* = 519) than with placebo (*n* = 515) after 12 weeks of treatment (22.6 vs. 15.3%) \[[@CR14]\] (primary endpoint \[[@CR7]\]), with the difference between the groups significantly favouring sarecycline after only 6 weeks of therapy \[[@CR14]\]. Changes from baseline in lesion counts with sarecycline and placebo at week 12 were consistent with these findings, including the mean absolute change in inflammatory lesion count (− 15.5 vs. − 11.1; no between-group statistical analyses reported) \[primary endpoint\] \[[@CR7]\], the LSM percentage change in inflammatory lesion count (− 49.9 vs. − 35.4%; *p* \< 0.0001) \[[@CR14]\] and the LSM absolute change in non-inflammatory lesion count (− 16.2 vs. − 13.4%; *p* \< 0.01) \[[@CR14]\]. Sarecycline was more favourable than placebo from week 3 of treatment onwards for each inflammatory lesion measure \[[@CR7], [@CR14]\] and week 9 onwards for the non-inflammatory lesion measure \[[@CR14]\]. Moreover, for the 48 and 62% of patients with chest or back acne at baseline (IGA score ≥ 2), the rate of success at these sites at 12 weeks was greater (*p* \< 0.05) with sarecycline than with placebo (36.6 vs. 21.6% and 33.2 vs. 25.7%) \[post hoc\] \[[@CR14]\]. Health-related quality of life measures at 12 weeks were also significantly more favourable with sarecycline than with placebo, including the symptoms, emotional, functioning and total scores of the Skindex-16 questionnaire. At baseline, the sarecycline and placebo groups had a mean facial inflammatory lesion count of 30.3 and 30.2, respectively, and a mean facial non-inflammatory lesion count of 42.3 and 43.9 \[[@CR14]\].

Patients who participated in SC1401 and SC1402 could receive sarecycline 1.5 mg/kg once daily in a longer-term phase 3 study (NCT02413346; SC1403) \[[@CR15]\]. This study (*n *= 483) was open-label and designed to assess safety \[[@CR15]\]; no efficacy data are available at present.

### Phase 2 {#Sec8}

Various once-daily doses of sarecycline (0.75, 1.5 and 3.0 mg/kg) were assessed in the treatment of moderate to severe facial acne vulgaris in patients aged 12--45 years in a phase 2 trial (PR-10411; NCT01628549) \[[@CR16]\]. Sarecycline 1.5 and 3.0 mg/kg once daily reduced inflammatory lesion counts, being significantly (*p* \< 0.05) more favourable than placebo for both the percentage LSM change from baseline (− 52.7 and − 51.8 vs. − 38.3%) and the absolute LSM change from baseline (− 16.9 and − 16.8 vs. − 12.5) after 12 weeks of treatment; corresponding changes with sarecycline 0.75 mg/kg once daily (− 42.5% and − 14) were not significant versus placebo. None of the sarecycline dosages (0.75, 1.5 or 3.0 mg/kg once daily) displayed significant benefit over placebo in terms of non-inflammatory lesion count changes at this timepoint (respective groups had LSM percentage changes from baseline of − 34.9, − 37.5 and − 32.3 vs. − 35.2% and LSM absolute changes from baseline of − 18, − 19.4 and − 17.6 vs. − 17.9). In this randomized, double-blind trial, a total of 284 patients were evaluable for efficacy, including 76, 70 and 66 in the sarecycline 0.75, 1.5 and 3.0 mg/kg groups and 72 in the placebo group. Across the groups, the mean inflammatory lesion count was 32.0--33.5 and the mean non-inflammatory lesion count was 50.6--54.6. Sarecycline was administered as capsules \[[@CR16]\].Key clinical trials of sarecycline (allergan)Drug(s)IndicationPhaseStatusLocation(s)IdentifierSarecycline tablets vs. placeboAcne vulgaris3CompletedUSANCT02320149 (SC1401)Sarecycline tablets vs. placeboAcne vulgaris3CompletedUSANCT02322866 (SC1402)Sarecycline tabletsAcne vulgaris3CompletedUSANCT02413346 (SC1403)Sarecycline capsules vs. placeboAcne vulgaris2CompletedUSANCT01628549 (PR-10411)

Adverse Events {#Sec9}
--------------

Sarecycline tablets administered at a dosage of 1.5 mg/kg once daily for 12 weeks were generally well tolerated in patients aged 9--45 years with moderate to severe facial acne vulgaris in the SC1401 and SC1402 phase 3 trials \[[@CR14]\]. The incidence of treatment-related adverse events (TRAEs) in the sarecycline and placebo group was 10.6 and 8.7% in SC1401 and 8.0 and 5.7% in SC1402. Treatment-emergent adverse events (TEAEs) were generally mild or moderate and the most common that occurred with a numerically greater incidence with sarecycline than with placebo was nausea (4.6 vs. 2.5% in SC1401; 1.9 vs. 1.0% in SC1402). Few TEAEs were serious (≤ 1.0% of patients in any group), none of which were considered to be related or possibly related to treatment, and no patients died in either trial. Study discontinuation because of TEAEs was also uncommon (≤ 2.1% of patients in any group), with most of these TEAEs being considered possibly related (SC1401 and SC1402) or related (SC1402) to study therapy. Other tetracycline-class antibiotics are often associated with certain gastrointestinal, vestibular and phototoxic adverse effects and, in females, vaginal yeast infections, although these TEAEs were generally uncommon with sarecycline. Among those that occurred with a numerically greater incidence with sarecycline than with placebo in SC1401 and/or SC1402 (nausea, vomiting, abdominal pain, abdominal discomfort, sunburn, vulvovaginal candidiasis and vulvovaginal mycotic infection), most occurred in \< 1.5% of sarecycline recipients, with the exception of nausea (in SC1401 and SC1402; see earlier discussion) and vomiting (in SC1401; 2.1 vs. 1.4% of placebo recipients) \[[@CR14]\].

The short-term tolerability of sarecycline is further supported by the phase 2 PR-10411 study that assessed sarecycline capsules at once-daily doses of 0.75, 1.5 or 3.0 mg/kg over 12 weeks \[[@CR16]\]. For instance, TRAEs occurred in 13.2% of sarecycline recipients (all doses pooled) and 9.6% of placebo recipients, the most common of which was nausea, although its incidence was numerically lower with sarecycline than with placebo (3.3 vs. 4.1%). TEAEs rarely led to discontinuation of therapy (one sarecycline 0.75 mg/kg recipient, four sarecycline 3.0 mg/kg recipients and one placebo recipient), with those considered to be TRAEs with sarecycline including hypoaesthesia, decreased white blood cell count and increased blood creatine phosphokinase \[[@CR16]\].

Longer term, most participants of SC1401 and SC1402 who entered the SC1403 safety trial experienced TEAEs with sarecycline 1.5 mg/kg once daily over a period of up to 40 weeks, regardless of whether they had originally received sarecycline (*n* = 247) or placebo (*n *= 236) in the parent trial (94% in each group) \[primary outcome measure\] \[[@CR15]\]. Patients in SC1403 received sarecycline until their facial acne had adequately improved and could re-start the drug if the acne returned \[[@CR15]\].

Ongoing Clinical Trials {#Sec10}
-----------------------

We are not aware of any sarecycline trials that are currently ongoing.

Current Status {#Sec11}
==============

Sarecycline received its first global approval in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years in the USA \[[@CR6]\].

This profile has been extracted and modified from the *AdisInsight* database. *AdisInsight* tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
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